Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price By: Investor Brand Network March 10, 2022 at 11:41 AM EST Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 12-month high of $100.00. Approximately 748,000 shares have changed hands today, as compared to an average 30-day volume of 1.4 million shares. Potential upside of 0.2% exists for Arena Pharmaceuticals Inc., based on a current level of $99.99 and analysts’ average consensus price target of $100.19. Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company’s pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain. In the past 12 months, Arena Pharmaceuticals Inc. share prices are bracketed by a low of $45.50 and a high of $100.00 and are now at $99.99, 120% above that low price. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN (InvestorBrandNetwork) IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal. For more information on IBN, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price By: Investor Brand Network March 10, 2022 at 11:41 AM EST Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 12-month high of $100.00. Approximately 748,000 shares have changed hands today, as compared to an average 30-day volume of 1.4 million shares. Potential upside of 0.2% exists for Arena Pharmaceuticals Inc., based on a current level of $99.99 and analysts’ average consensus price target of $100.19. Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company’s pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain. In the past 12 months, Arena Pharmaceuticals Inc. share prices are bracketed by a low of $45.50 and a high of $100.00 and are now at $99.99, 120% above that low price. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN (InvestorBrandNetwork) IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal. For more information on IBN, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 12-month high of $100.00. Approximately 748,000 shares have changed hands today, as compared to an average 30-day volume of 1.4 million shares. Potential upside of 0.2% exists for Arena Pharmaceuticals Inc., based on a current level of $99.99 and analysts’ average consensus price target of $100.19. Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company’s pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain. In the past 12 months, Arena Pharmaceuticals Inc. share prices are bracketed by a low of $45.50 and a high of $100.00 and are now at $99.99, 120% above that low price. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN (InvestorBrandNetwork) IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal. For more information on IBN, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
